Swiftpharma
ActiveSummary
The computed 12-month bankruptcy probability of Swiftpharma is 2.0% (moderate). The annual accounts of Swiftpharma for financial year 2025 show a net loss of 68% of the equity at the start of that year. The 2025 annual accounts show equity of €834,755 and a net result of -€1.8m. Equity is growing by about 46% per year across the filed financial years. Its solvency ranks better than 24% of 9,760 sector peers (NACE 46, financial year 2025). The company has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
23-09
Gazette deed
Appointments: TOUWEN Jasper Lode (director) and SCHIPPER Daniel Bernard (director)Resignation: PERRENET Raymond Roger (director) · Auditor report · Capital increase20 facts ▸
Gazette deed
Appointments: TOUWEN Jasper Lode (director) and SCHIPPER Daniel Bernard (director)
Resignation: PERRENET Raymond Roger (director) · Auditor report · Capital increase20 facts ▸
- General meeting, 15-09-2026 (2 times)
- Auditor report, 15-09-2026 (2 times)
- General meeting, “Goedkeuring en ratificatie van de CLA” (deed in Dutch)
- General meeting, “Afstand van het voorkeurrecht” (deed in Dutch)
- Capital increase, €1,700,000 (2 times)
- General meeting, 1700000.0, EUR
- General meeting, “Vaststelling van de verwezenlijking van de bijkomende inbreng” (deed in Dutch)
- Capital increase, €1,521,764 (2 times)
- Amendment of the articles, 5
- Amendment of the articles (2 times)
- Capital
- Power of attorney
- +8 further facts in this act
27-04
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
03-12
Gazette deed
Registered officeRegistered-office move2 facts ▸
Gazette deed
Registered office
Registered-office move2 facts ▸
- Board meeting, 21-10-2025
- Registered-office move, Thor Park 8027,bus 0215,3600 Genk
08-10
Gazette deed
Resignation: Bart Goddyn (director)Permanent representative: Jeroen Hofenk3 facts ▸
Gazette deed
Resignation: Bart Goddyn (director)
Permanent representative: Jeroen Hofenk3 facts ▸
- Board meeting, 07-09-2025
- Director resignation, Bart Goddyn (director)
- Permanent representative, Jeroen Hofenk
08-08
Gazette deed
Resignation: JV Health BV (class A director)Permanent representative: Johan Van Havermaet · Appointment: Bart Goddyn (class A director)6 facts ▸
Gazette deed
Resignation: JV Health BV (class A director)
Permanent representative: Johan Van Havermaet · Appointment: Bart Goddyn (class A director)6 facts ▸
- Board meeting, 02-04-2025
- General meeting, 30-05-2025
- Director resignation, JV Health BV (class A director)
- Permanent representative, Johan Van Havermaet
- Director appointment, Bart Goddyn (class A director)
- Director appointment, Bart Goddyn (director)
17-06
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format
10-01
Gazette deed
Resignation: Asterion Research & Development BV (director)Appointment: HofMan BV (director) · Permanent representative: Jeroen Hofenk4 facts ▸
Gazette deed
Resignation: Asterion Research & Development BV (director)
Appointment: HofMan BV (director) · Permanent representative: Jeroen Hofenk4 facts ▸
- General meeting, 25-11-2024
- Director resignation, Asterion Research & Development BV (director)
- Director appointment, HofMan BV (director)
- Permanent representative, Jeroen Hofenk
2024
31-12
Financial
Weakest financial yearnet -€1.9m
Net result drops to -€1.9m, the lowest in the series; recovery starts the following year.
31-12
Financial
Liquidity more than 5 timescurrent ratio 1.80
Current ratio from 0.34 to 1.80.
31-12
Financial
Equity above €2mequity €2.6m ▲4,241%
Equity rises from €59,560 to €2.6m.
01-10
Gazette deed
Appointment: PERRENET Raymond (director)Permanent representatives: HOFENK Jeroen and VAN HAVERMAET Johan · Capital increase · Bank account12 facts ▸
Gazette deed
Appointment: PERRENET Raymond (director)
Permanent representatives: HOFENK Jeroen and VAN HAVERMAET Johan · Capital increase · Bank account12 facts ▸
- General meeting, 27-09-2024
- Capital increase, €4,410,000
- Bank account, “dossier notaris, artikel 5:132 Wetboek van vennootschappen en verenigingen” (deed in Dutch)
- Amendment of the articles, 5
- Amendment of the articles
- Capital
- Director appointment, PERRENET Raymond (director)
- Board composition, ASTERION RESEARCH & DEVELOPMENT (class A director)
- Board composition, JVHealth (class A director)
- Board composition, PERRENET Raymond (class B director)
- Permanent representative, HOFENK Jeroen
- Permanent representative, VAN HAVERMAET Johan
25-07
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format
01-02
Gazette deed
Permanent representative: Christian DeprezResignation: BV CHRISTIAN DEPREZ CONSULTING (director)3 facts ▸
Gazette deed
Permanent representative: Christian Deprez
Resignation: BV CHRISTIAN DEPREZ CONSULTING (director)3 facts ▸
- Permanent representative, Christian Deprez
- General meeting, “verhogen van de vergadering, geen verdere punten” (deed in Dutch)
- Director resignation, BV CHRISTIAN DEPREZ CONSULTING (director)
2023
02-10
Gazette deed
Resignation: Christian Deprez (manager)2 facts ▸
Gazette deed
Resignation: Christian Deprez (manager)
2 facts ▸
- General meeting, 23-08-2023
- Director resignation, Christian Deprez (manager)
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
8 of 11 deeds read
About the unread acts
Of the 11 Belgian Official Gazette deeds we know for this company, 8 have been read. The other 3 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.